High level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer

Ítems similars

• Immunogenic cell death by neoadjuvant oxaliplatin and radiation protects against metastatic failure in high-risk rectal cancer
  per: Bains, Simer J., et al.
  Publicat: (2019)
• Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer
  per: Kalanxhi, Erta, et al.
  Publicat: (2018)
• Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer
  per: Hektoen, Helga Helseth, et al.
  Publicat: (2015)
• Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer
  per: Meltzer, Sebastian, et al.
  Publicat: (2016)
• MRI volumetry for prediction of tumour response to neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced rectal cancer
  per: Seierstad, T, et al.
  Publicat: (2015)